What is the appropriate management for a patient with mild hyponatremia, borderline hypoglycemia, non‑anion‑gap metabolic acidosis, low calcium, elevated BUN and creatinine (eGFR 35 mL/min/1.73 m²) consistent with stage 3 chronic kidney disease?

Management of Stage 3 CKD with Metabolic Acidosis and Mild Hyponatremia

For this patient with eGFR 35 mL/min/1.73 m² (Stage 3b CKD), bicarbonate 18 mEq/L, and sodium 132 mmol/L, initiate oral sodium bicarbonate supplementation immediately to target bicarbonate ≥22 mmol/L, which will simultaneously address both the metabolic acidosis and mild hyponatremia.

Metabolic Acidosis Management (Priority #1)

The bicarbonate of 18 mEq/L meets the threshold for treatment according to the most recent KDIGO 2024 guidelines 1. Bicarbonate supplementation is specifically recommended when levels are less than 18 mmol/L 2, and this patient sits exactly at that threshold with non-anion gap metabolic acidosis (anion gap 14.2 mmol/L is normal).

Why Treat at This Level:

• The 2024 KDIGO guidelines significantly modified their 2012 recommendations after negative bicarbonate supplementation trials, now recommending treatment only when bicarbonate <18 mmol/L 2
• Treatment at this stage preserves eGFR and reduces kidney angiotensin II activity 3
• Untreated metabolic acidosis drives CKD progression and causes protein catabolism, bone disease, and muscle wasting 4

Treatment Options (in order of preference):

Option 1: Oral Sodium Bicarbonate

• Start 650-1300 mg (1-2 tablets) three times daily
• Target bicarbonate ≥22 mmol/L 4
• Recheck electrolytes in 2-4 weeks
• Advantage: Will simultaneously help correct the mild hyponatremia by providing sodium load

Option 2: Dietary Alkali (Fruits and Vegetables)

• Increase base-producing fruits and vegetables to reduce dietary acid by 50% 3
• Equally effective as bicarbonate for preserving eGFR 3
• Disadvantage: Won't address the hyponatremia as directly

Hyponatremia Management (Priority #2)

The sodium of 132 mmol/L represents mild, likely asymptomatic hyponatremia. The approach depends on volume status assessment:

Critical Assessment Needed:

• Volume status: Examine for signs of hypovolemia (orthostatic hypotension, poor skin turgor) vs. euvolemia vs. hypervolemia (edema, elevated JVP)
• Symptom assessment: Weakness, nausea, confusion, gait disturbances (though mild hyponatremia is often asymptomatic)

Treatment Strategy:

If Euvolemic (likely SIADH):

• Adequate solute intake (salt and protein) 5
• Initial fluid restriction 500 mL/day, adjusted based on sodium response 5
• Important caveat: Nearly half of SIADH patients don't respond to fluid restriction as first-line therapy 5
• If fluid restriction fails after 48-72 hours, consider oral urea (15-30 g/day) as second-line—safe, effective, and inexpensive 5, 6
• Vaptans (tolvaptan) are alternative but expensive and risk overcorrection 6

If Hypovolemic:

• Isotonic saline (0.9% NaCl) to restore volume
• Address underlying cause (diuretic adjustment, GI losses)

If Hypervolemic (heart failure, cirrhosis):

• Fluid restriction
• Optimize diuretic therapy
• Consider vaptans if refractory 7

The sodium bicarbonate therapy for acidosis will provide additional sodium, which should help correct the mild hyponatremia without aggressive intervention 5.

Additional CKD Management Priorities

Borderline Hypoglycemia (Glucose 63 mg/dL):

• Assess for medication-induced hypoglycemia (sulfonylureas, insulin)
• Reduced renal clearance of insulin in CKD increases hypoglycemia risk
• Adjust diabetic medications if present
• Ensure adequate caloric intake

Hypocalcemia (Calcium 8.2 mg/dL):

• Check intact PTH, 25-OH vitamin D, phosphorus
• Likely secondary hyperparathyroidism from CKD
• Consider vitamin D supplementation if deficient
• Calcium supplementation if symptomatic or PTH elevated

Elevated BUN/Creatinine:

• BUN 23 mg/dL with creatinine 1.51 mg/dL suggests intrinsic kidney disease
• Initiate or optimize RAS inhibition (ACE inhibitor or ARB) if not contraindicated 1
• Check urine albumin-to-creatinine ratio to guide therapy
• Consider SGLT2 inhibitor if eGFR ≥20 mL/min/1.73 m² and ACR ≥200 mg/g 1

Monitoring Plan

Within 2-4 weeks:

• Recheck basic metabolic panel (sodium, potassium, bicarbonate, creatinine)
• Assess response to bicarbonate therapy
• Evaluate hyponatremia correction (target gradual increase of 4-6 mEq/L over days, not hours) 5

Avoid overcorrection: Rapid correction >10 mEq/L in 24 hours risks osmotic demyelination syndrome 7

Common Pitfalls

• Don't use hypertonic saline for this mild, asymptomatic hyponatremia—reserved only for severely symptomatic patients with seizures, coma, or cardiorespiratory distress 7
• Don't withhold bicarbonate based on outdated concerns about sodium overload—the benefits at bicarbonate <18 mEq/L outweigh risks 2
• Don't aggressively fluid restrict without first ensuring adequate solute intake, as this can worsen outcomes 5
• Monitor potassium closely when initiating RAS inhibition in CKD patients—current potassium 4.4 mmol/L is acceptable for starting therapy 1